Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARA trial: tapering conventional DMARDs versus anti-TNF first in rheumatoid arthritis remission
NL-OMON41388Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept, adalimumab, certolizumab pegol, golimumab and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Erasmus MC. Primary endpoints: Disease flare during first year and Incremental cost-effectiveness ratio. Started Jun 2011; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41388.